News

Shares of iPhone and iPad maker Apple (NASDAQ:AAPL) fell 4.1% in the morning session after the company reported mixed first-quarter 2025 (fiscal Q2) results, which narrowly topped analysts' revenue expectations, amid tariff concerns. CEO Tim Cook stated during the earnings call that anticipated tariffs could cost the company around $900 million in the current quarter (about 1% of total revenue). Also, sales in China saw a decline of 2%. This is a crucial market for Apple, and any signs of weakne

Shares of DexCom jumped over 15% to pace the S&P 500's advancers Friday, a day after the maker of glucose monitoring devices for people with diabetes reported better-than-expected quarterly revenue.

“The data is almost secondary at this point,” JPMorgan’s Bill Eigen said in a television interview Friday, before the jobs report came out.

Duolingo shares soared to a record high Friday, a day after the language education platform topped estimates for the first quarter.

Shares of streaming TV platform Roku (NASDAQ: ROKU) fell 11.2% in the morning session after the company reported weak first quarter 2025 results: its revenue outlook for next quarter missed significantly, and it pulled its full-year guidance for advertising revenue, raising concerns about visibility into a core part of its business. On the other hand, Roku blew past analysts' EPS expectations this quarter. Still, this was a softer quarter.

Shares of live sports and TV streaming service fuboTV (NYSE:FUBO) fell 14.9% in the morning session after the company reported underwhelming first quarter 2025 results with revenue missing analysts' estimates significantly.

Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 15.2% in the morning session after the company reported strong first quarter 2025 results which beat analysts' revenue and EBITDA expectations and included full-year revenue guidance that slightly exceeded Wall Street's estimates. Sales grew 11% from the previous year, driven by a 14% rise in screening revenue, while precision oncology grew more modestly at 4% on a core basis. The sales bump largely came from the expans